Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) Director Paul Manning acquired 550,458 shares of the stock in a transaction dated Monday, February 23rd. The stock was acquired at an average price of $5.45 per share, for a total transaction of $2,999,996.10. Following the completion of the transaction, the director directly owned 2,763,527 shares of the company's stock, valued at approximately $15,061,222.15. This represents a 24.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Candel Therapeutics Stock Down 0.6%
CADL opened at $5.15 on Friday. The company has a market capitalization of $282.74 million, a PE ratio of -9.03 and a beta of -0.94. Candel Therapeutics, Inc. has a 52 week low of $4.25 and a 52 week high of $9.13. The firm has a 50-day simple moving average of $5.77 and a two-hundred day simple moving average of $5.50. The company has a quick ratio of 8.25, a current ratio of 8.25 and a debt-to-equity ratio of 0.01.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its holdings in shares of Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company's stock valued at $40,000 after acquiring an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company's stock valued at $49,000 after acquiring an additional 7,527 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Candel Therapeutics during the 4th quarter worth approximately $51,000. Invesco Ltd. purchased a new stake in Candel Therapeutics in the first quarter valued at $59,000. Finally, ProShare Advisors LLC purchased a new stake in Candel Therapeutics in the 4th quarter valued at about $59,000. 13.93% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
CADL has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Citigroup reduced their price target on Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday, November 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Candel Therapeutics in a research report on Wednesday, January 21st. Stephens reissued an "overweight" rating and issued a $15.00 price objective on shares of Candel Therapeutics in a report on Monday, December 8th. Finally, Zacks Research lowered shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday, January 19th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $17.00.
Read Our Latest Stock Report on CADL
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.
In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
